Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis

被引：0
|
作者：
Joshua D. Wallach
Anita T. Luxkaranayagam
Sanket S. Dhruva
Jennifer E. Miller
Joseph S. Ross
机构：
[1] Yale School of Public Health,Department of Environmental Health Sciences
[2] Yale Law School,Collaboration for Research Integrity and Transparency (CRIT)
[3] Center for Outcomes Research and Evaluation (CORE),Department of Medicine
[4] Yale-New Haven Hospital,Section of General Medicine, Department of Internal Medicine
[5] University of Connecticut,National Clinician Scholars Program, Department of Internal Medicine
[6] University of California,Department of Health Policy and Management
[7] San Francisco School of Medicine,undefined
[8] Section of Cardiology,undefined
[9] San Francisco Veterans Affairs Health Care System,undefined
[10] Yale School of Medicine,undefined
[11] Yale School of Medicine,undefined
[12] Yale School of Public Health,undefined
来源：
BMC Medicine | / 17卷
关键词：
Postmarketing commitments; Postmarketing requirements; FDA; Lifecycle evaluation; Pharmaceutical regulation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Dermatology-related postmarketing study commitments to the Food and Drug Administration
    Bognet, Rachel A.
    Chiang, David S.
    Katz, Kenneth A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (04) : 721 - 723
  • [22] Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017
    Zhu, Xingyue
    Liu, Bao
    BMJ OPEN, 2022, 12 (07):
  • [23] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
    Kayki-Mutlu, Gizem
    Aksoyalp, Zinnet Sevval
    Wojnowski, Leszek
    Michel, Martin C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2022, 395 (08) : 867 - 885
  • [24] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
    Gizem Kayki-Mutlu
    Martin C. Michel
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394 : 839 - 852
  • [25] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023
    Gizem Kayki-Mutlu
    Zinnet Sevval Aksoyalp
    Leszek Wojnowski
    Martin C. Michel
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2024, 397 : 2949 - 2970
  • [26] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024
    Zinnet Sevval Aksoyalp
    Gizem Kayki-Mutlu
    Leszek Wojnowski
    Martin C. Michel
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2025, 398 (5) : 5077 - 5099
  • [27] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
    Gizem Kayki-Mutlu
    Zinnet Sevval Aksoyalp
    Leszek Wojnowski
    Martin C. Michel
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395 : 867 - 885
  • [28] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023
    Kayki-Mutlu, Gizem
    Aksoyalp, Zinnet Sevval
    Wojnowski, Leszek
    Michel, Martin C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 (05) : 2949 - 2970
  • [29] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
    Gizem Kayki-Mutlu
    Zinnet Sevval Aksoyalp
    Leszek Wojnowski
    Martin C. Michel
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 1619 - 1632
  • [30] A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
    Kayki-Mutlu, Gizem
    Aksoyalp, Zinnet Sevval
    Wojnowski, Leszek
    Michel, Martin C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2023, 396 (08) : 1619 - 1632
12345